Search

Author/Creator Flinn, I.

1. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. (12th June 2019)

Authors:
Wang, M.; Belada, D.; Cheah, C.; Chu, M.P.; Dreyling, M.; Flinn, I.; Fogliatto, L.; Goy, A.; Inwards, D.; Jurczak, W.; Mayer, J.; Re, F.; Robak, T.; Spurgeon, S.; Yoon, S.S.; Zinzani, P.L.; Yin, M.; Chen, T.; Kahl, B.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
554
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. (12th June 2019)

Authors:
Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
114
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. (12th June 2019)

Authors:
Gribben, J.; Trneny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Leonard, J.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
227
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. (June 2017)

Authors:
Zinzani, P.; Wagner‐Johnston, N.; Miller, C.; Ardeshna, K.; Tertreault, S.; Assouline, S.; Mayer, J.; Passamonti, F.; Lunin, S.; Pettitt, A.; Nagy, Z.; Tournilhac, O.; Abou‐Nassar, K.; Crump, M.; Jacobsen, E.; De Vos, S.; Youssoufian, H.; Porter, J.; Prado, S.; Flinn, I.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017)

Authors:
Tam, C.S.; Byrd, J.C.; O'Brien, S.; Coutre, S.; Barr, P.M.; Furman, R.R.; Kipps, T.J.; Burger, J.A.; Stevens, D.; Sharman, J.; Ghia, P.; Flinn, I.; Zhou, C.; Ninomoto, J.; James, D.F.; Wierda, W.G.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
233
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. (12th June 2019)

Authors:
Radford, J.; Connors, J.M.; Younes, A.; Gallamini, A.; Ansell, S.M.; Kim, W.S.; Cheong, J.; Flinn, I.; Kalakonda, N.; Kaminski, M.; Pettengell, R.; Onsum, M.; Josephson, N.; Kuroda, S.; Liu, R.; Miao, H.; Gautam, A.; Trepicchio, W.L.; Sureda, A.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
290
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY. (June 2017)

Authors:
Flinn, I.; van der Jagt, R.; Chang, J.; Wood, P.; Hawkins, T.; MacDonald, D.; Trotman, J.; Simpson, D.; Kolibaba, K.; Issa, S.; Hallman, D.; Chen, L.; Burke, J.M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
140
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019)

Authors:
Sehn, L.H.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Diefenbach, C.M.; Flinn, I.; Hong, J.Y.; Kim, W.S.; Matasar, M.; Nastoupil, L.; Schuster, S.J.; Shadman, M.; Yoon, S.S.; Bender, B.; Chu, W.; Hernandez, G.M.; Kwan, A.; McCall, B.; Sison, I.; Wang, C.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
310
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. (23rd June 2022)

Authors:
Eyre, T. A.; Wang, M. L.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Vandenberghe, E.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; Wang, Y.; Coombs, C. C.; Flinn, I.; Lewis, D.; Le Gouill, S.; Gandhi, M.; Chay, C.; Palomba, M. L.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
991
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P1191: ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN- AND PATIENT-REPORTED OUTCOMES IN THE POLARIX STUDY. (23rd June 2022)

Authors:
Trněný, M.; Fogliatto, L.; Gardner, F.; Flinn, I.; Larouche, J.-F.; Haioun, C.; Canales, M.; Goto, H.; Hajek, R.; Salles, G.; Qiu, J.; Campinha-Bacote, A.; Yan, M.; Kothari, R.; Man, G.; Sahin, D.; Hirata, J.; Lee, C.; Tilly, H.; Flowers, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1077
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗